| IL-6 |
Tocilizumab |
Inhibit IL-6-mediated signaling involving ubiquitous signal-transducing |
Appeared on the market in 2010 |
|
|
Sarilumab |
gp130 and STAT3 |
Phase III |
|
|
Clazakizumab |
|
Phase II B |
|
|
ALX-0061 |
|
Phase II |
|
|
|
|
|
| IL-1 |
Anakinra |
Blocks IL-1 binding to IL-1RI, resulting in intracellular signaling |
Appeared on the market in 2001 |
|
|
|
|
|
| IL-12/23 |
Ustekinumab |
Bind to the cytokines IL-12 and IL-23 and down-modulate lymphocyte |
Appeared on the market in 2005 |
|
|
Canakinumab |
function |
Appeared on the market in 2009 |
|
|
|
|
|
| TNF-α |
Infliximab |
Induce antibody-dependent cytotoxicity (ADCC); the complement |
Appeared on the market in 1998 |
|
|
Adalimumab |
pathway triggers cell-dependent cytotoxicity (CDC) and targets immune |
Appeared on the market in 2002 |
|
|
Etanercept |
cell apoptosis |
Appeared on the market in 1998 |
|
|
Golimumab |
|
Appeared on the market in 2009 |
|
|
Certolizumab |
|
Appeared on the market in 2008 |
